🔗 Share this article

While the United States proceeds with sweeping adjustments to its vaccine schedules, a particular individual appears unexpectedly: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by casting doubt on Covid vaccinations during the global health crisis and has zeroed in on potential fatalities following COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders planned to reveal radical revisions to the childhood immunization program recently, aligning the US with Denmark’s vaccine program, sources say – a major change that would place the US out of alignment with a large portion of the world with little proof for benefit. This reveal has been delayed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to present at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a strengthened alliance between the drug and biologics centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing some pediatric vaccine recommendations in the US in order to be more similar to the Danish model, a society with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

So far public appearances, she has continued to focus on vaccines – usually the responsibility of Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Qualifications

The appointee has no obvious background in medication creation, regulation or management, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in managing a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp regulatory frameworks and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she lacks the sort of resume that prior appointees who headed the center have had.”

The drug center has an enormous workload at the agency, Woodcock stated.

“The public just pays attention on the new drug program, but the generic drug division approves thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and each of these need to be managed,” Dr. Woodcock noted. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant management component to the job, which oversees in excess of 5,000 staff members. “It’s a massive administrative position, if you execute it properly,” she said.

Official Statement and Disputed Programs

Regarding inquiries about Dr. Høeg's credentials and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a press secretary stated that the “inquiries are based on incorrect presumptions”.

“Her resume is consistent with the responsibilities of her position,” the spokesperson stated, noting the months Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg takes over the agency head's new fast-track approval initiative, a contentious rapid drug-approval program that allegedly concerned her former heads. “How are these drugs being selected for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he stated, “the FDA looks to be trending towards laxer regulations of pharmaceuticals, with the exception of shots.”

Established Track Record on Vaccines

With vaccines, Høeg has a more established, if problematic, track record, some experts have noted. She authored a analysis using unverified crowd-sourced reports to estimate the rate of myocarditis after Covid immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the current government included revising guidelines for new vaccines and halting “non-essential” immunizations, she remarked following the vote on a audio program. At the FDA, Høeg has reportedly proposed preventing adolescent males from getting COVID-19 vaccines.

“She’s an thorough ideologue who commences with her preconceived notions and tailors the evidence to accommodate the science in a highly deceptive, dishonest way,” Howard argued.

Gaining Influence and a “Revenge Tour”

Høeg became part of other contrarians, {like|